pyrazines has been researched along with lactacystin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; Chau, V; Elliott, PJ; Lightcap, ES; McCormack, TA; Pien, CS | 1 |
| An, WG; Blagosklonny, MV; Hwang, SG; Trepel, JB | 1 |
| Schenkein, D | 1 |
| Luker, GD; Luker, KE; Pica, CM; Piwnica-Worms, D; Song, J | 1 |
| Daniel, KG; Dou, QP; Kazi, A; Kuhn, DJ | 1 |
| Chizzolini, C; Dayer, JM; Fineschi, S; Guerne, PA; Reith, W | 1 |
| Berges, C; Daniel, V; Fuchs, D; Höh, A; Miltz, M; Naujokat, C; Opelz, G; Ovens, J; Sadeghi, M; Wieczorek, H | 1 |
| Anselmino, A; Atzori, C; Cargnel, A; Mazza, F; Piccinini, M; Rinaudo, MT; Tronconi, E; Valerio, A | 1 |
| Blau, IW; Busse, A; Driessen, C; Keilholz, U; Kraus, M; Na, IK; Rietz, A; Scheibenbogen, C; Thiel, E | 1 |
| Berges, C; Daniel, V; Fuchs, D; Haberstock, H; Miltz, M; Naujokat, C; Opelz, G; Sadeghi, M | 1 |
| Chen, D; Dou, QP; Landis-Piwowar, KR; Milacic, V; Yang, H | 1 |
| Tsukamoto, S; Yokosawa, H | 1 |
| Alden, CL; Cardoza, K; Csizmadia, E; Csizmadia, V; Fedyk, ER; Gallacher, M; Kadambi, VJ; O'Brien, L; Raczynski, A; Silverman, L; Simpson, C | 1 |
| David, CS; Patel, R; Rajagopalan, G; Theuer, JE; Tilahun, AY | 1 |
| Bui, TN; Efuet, ET; Keyomarsi, K | 1 |
| Li, J; Wu, XM; Zhang, DY | 1 |
| Azakir, BA; Di Fulvio, S; Kinter, J; Sinnreich, M | 1 |
| Al-Husein, B; Al-Shabrawey, M; Bollag, WB; Choudhary, V; Davis, M; Dong, Z; El Gaish, M; Kaddour-Djebbar, I; Kumar, MV; Lakshmikanthan, V; Shirley, R; Zhong, R | 1 |
| Bader, M; Grassner, L; Knight, AM; Loprinzi, CL; Paz, J; Podratz, JL; Staff, NP; Trushina, E; Windebank, AJ | 1 |
5 review(s) available for pyrazines and lactacystin
| Article | Year |
|---|---|
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Topics: Acetylcysteine; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Curcumin; Humans; Neoplasms; Pentacyclic Triterpenes; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Triterpenes; Ubiquitin | 2008 |
Targeting the proteasome pathway.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Discovery; Humans; Lactones; Neoplasms; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitins | 2009 |
[Classification and synthesis of ubiquitin-proteasome inhibitor].
Topics: Acetylcysteine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Dipeptides; Humans; Multiple Myeloma; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2009 |
14 other study(ies) available for pyrazines and lactacystin
| Article | Year |
|---|---|
Proteasome inhibition measurements: clinical application.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; In Vitro Techniques; Kinetics; Male; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2000 |
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Topics: Acetylcysteine; Acrylates; Amino Acid Chloromethyl Ketones; Apoptosis; Boronic Acids; Bortezomib; Calpain; Cathepsins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Drug Synergism; Genes, p53; Humans; Jurkat Cells; Leupeptins; Multienzyme Complexes; Neoplasm Proteins; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; U937 Cells | 2000 |
Imaging 26S proteasome activity and inhibition in living mice.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Coleoptera; Cysteine Proteinase Inhibitors; Genes, Reporter; HeLa Cells; Humans; Kinetics; Leupeptins; Luciferases; Luminescent Measurements; Male; Mice; Mice, Nude; Molecular Biology; Peptide Hydrolases; Proteasome Endopeptidase Complex; Pyrazines; Transfection; Ubiquitin; Xenograft Model Antitumor Assays | 2003 |
Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.
Topics: Acetylcysteine; Anthracenes; Boronic Acids; Bortezomib; Collagen Type I; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Matrix; Fibroblasts; Fibrosis; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Leupeptins; Matrix Metalloproteinase 1; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-jun; Pyrazines; RNA Polymerase II; RNA, Messenger; Scleroderma, Systemic; Skin; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Up-Regulation | 2006 |
Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.
Topics: Acetylcysteine; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Chymases; Cysteine Proteinase Inhibitors; Dendritic Cells; Endocytosis; Humans; Interleukin-12; Lymphocyte Activation; Monocytes; Oligopeptides; Pinocytosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, Cell Surface | 2007 |
Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Line; Coumarins; Genes, Fungal; HIV Protease Inhibitors; Humans; Lopinavir; Models, Animal; Oligopeptides; Pneumocystis carinii; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrimidinones; Rats | 2006 |
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Topics: Acetylcysteine; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Lymphoma; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines | 2008 |
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Topics: Acetylcysteine; Antigens, CD; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Immunologic; Humans; Immunosuppressive Agents; Lymphocyte Activation; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translocation, Genetic; Tumor Suppressor Protein p53 | 2008 |
Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
Topics: Acetylcysteine; Animals; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Oligopeptides; PC12 Cells; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Ubiquitin | 2010 |
Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation.
Topics: Acetylcysteine; Animals; Apoptosis; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Cytokines; HLA-DR3 Antigen; Lipopolysaccharides; Liver; Mice; Mice, Transgenic; NF-kappa B; Proteasome Inhibitors; Pyrazines; Superantigens; Systemic Inflammatory Response Syndrome | 2010 |
Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
Topics: Acetylcysteine; Animals; Biological Assay; Boronic Acids; Bortezomib; Cell Extracts; Cells, Cultured; Chymotrypsin; High-Throughput Screening Assays; Inhibitory Concentration 50; Leupeptins; Mice; Models, Biological; Oligopeptides; Ornithine Decarboxylase; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Time Factors | 2011 |
Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.
Topics: Acetylcysteine; Alleles; Amino Acid Substitution; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Proteinase Inhibitors; Distal Myopathies; Dysferlin; Humans; Membrane Proteins; Muscle Fibers, Skeletal; Muscle Proteins; Muscular Atrophy; Muscular Dystrophies, Limb-Girdle; Mutation, Missense; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; RNA, Messenger | 2012 |
Diltiazem enhances the apoptotic effects of proteasome inhibitors to induce prostate cancer cell death.
Topics: Acetylcysteine; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Humans; Male; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Transfection; Tumor Cells, Cultured | 2012 |
Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Axonal Transport; Boronic Acids; Bortezomib; Cell Death; Cells, Cultured; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Embryo, Mammalian; Ganglia, Spinal; Microscopy, Electron, Transmission; Microtubules; Neurons; Organ Culture Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Time Factors | 2013 |